

DAFTAR PUSTAKA

- Abdul-razzaq, M.S., Al-khafaji, J.K.T., 2014. Molecular characterization of capsular polysaccharide genes of *Klebsiella pneumoniae* in Iraq. *Int.J.Curr.Microbiol.App.Sci* 3, 224–234.
- Al-Hasan, M.N., Wilson, J.W., Lahr, B.D., Thomsen, K.M., Eckel-Passow, J.E., Vetter, E.A., Tleyjeh, I.M., Baddour, L.M., 2009. Beta-Lactam and Fluoroquinolone Combination Antibiotic Therapy for Bacteremia Caused By Gram-Negative Bacilli. *Antimicrob. Agents Chemother.* 53, 1386–1394. doi:10.1128/AAC.01231-08
- Aikawa, N., Fujishima, S., Endo, S., Sekine, I., Kogawa, K., Yamamoto, Y., Kushimoto, S., Yukioka, H., Kato, N., Totsuka, K., Kikuchi, K., Ikeda, T., Ikeda, K., Harada, K., Satomura, S., 2005. Multicenter prospective study of procalcitonin as an indicator of sepsis. *J. Infect. Chemother.* 11, 152–159. doi:10.1007/s10156-005-0388-9
- Alexiou, V.G., Michalopoulos, a, Makris, G.C., Peppas, G., Samonis, G., Falagas, M.E., 2012. Multi-drug-resistant gram-negative bacterial infection in surgical patients hospitalized in the ICU: a cohort study. *Eur. J. Clin. Microbiol. Infect. Dis.* 31, 557–66. doi:10.1007/ s10096-011-1347-2
- Antimicrobial Resistance global report on surveillance 2014, 2014.
- Bassetti, M., Peghin, M., Pecori, D., 2016. The management of Multidrug Resistant *Enterobacteriaceae*. *Curr Opin Infect Dis.* 29, 583–594.
- Beceiro, A., Tomás, M., Bou, G., 2013. Antimicrobial resistance and virulence: A successful or deleterious association in the bacterial world? *Clin. Microbiol. Rev.* 26, 185–230. doi:10.1128/CMR.00059-12
- Ben-David, D., Kordevani, R., Keller, N., Tal, I., Marzel, a., Gal-Mor, O., Maor, Y., Rahav, G., 2012. Outcome of carbapenem resistant *Klebsiella pneumoniae* bloodstream infections. *Clin. Microbiol. Infect.* 18, 54–60. doi:10.1111/j.1469-0691.2011.03478.x
- Bhavnani, S.M., Ambrose, P.G., Craig, W. a., Dudley, M.N., Jones, R.N., 2006. Outcomes evaluation of patients with ESBL- and non-ESBL-producing *Escherichia coli* and *Klebsiella* species as defined by CLSI reference methods: Report from the SENTRY Antimicrobial Surveillance Program. *Diagn Microbiol Infect Dis* 54, 231–236. doi:10.1016/j.diagmicrobio.2005.09.011
- Black, J. a., Moland, E.S., Thomson, K.S., 2005. AmpC disk test for detection of plasmid-mediated AmpC β -lactamases in *Enterobacteriaceae* lacking chromosomal AmpC β -lactamases. *J. Clin. Microbiol.* 43, 3110–3113. doi:10.1128/JCM.43.7.3110-3113.2005

- Bonini, P., Plebani, M., Ceriotti, F., Rubboli, F., 2002. Errors in laboratory medicine. *Clin. Chem.* 48, 691–698.
- Bora, A., Sanjana, R., Jha, B., Narayan Mahaseth, S., Pokharel, K., 2014. Incidence of metallo-beta-lactamase producing clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* in central Nepal. *BMC Res. Notes* 7, 557. doi:10.1186/1756-0500-7-557
- Borer, A., Saidel-Odes, L., Riesenber, K., Eskira, S., Peled, N., Nativ, R., Schlaeffer, F., Sherf, M., 2009. Attributable mortality rate for carbapenem-resistant *Klebsiella pneumoniae* bacteremia. *Infect. Control Hosp. Epidemiol.* 30, 972–976. doi:10.1086/605922
- Bradford, P., 2001. Extended-Spectrum β -Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. *Clin Microbiol Rev.* 14, 933–951. doi:10.1128/CMR.14.4.933
- Bréchet, N., Hékimian, G., Chastre, J., Luyt, C., 2015. Procalcitonin to guide antibiotic therapy in the ICU. *Int J Antimicrob Agents* 46, S19–S24. doi:10.1016/j.ijantimicag.2015.10.012
- Brisse, S., van Himbergen, T., Kusters, K., Verhoef, J., 2004. Development of a rapid identification method for *Klebsiella pneumoniae* phylogenetic groups and analysis of 420 clinical isolates. *Clin. Microbiol. Infect.* 10, 942–945. doi:10.1111/j.1469-0691.2004.00973.x
- Brisse, S., Verhoef, J., 2001. Phylogenetic diversity of *Klebsiella pneumoniae* and *Klebsiella oxytoca* clinical isolates revealed by randomly amplified polymorphic DNA, *gyrA* and *parC* genes sequencing and automated ribotyping. *Int. J. Syst. Evol. Microbiol.* 51, 915–924. doi:10.1099/00207713-51-3-915
- Bush, K., Jacoby, G. a, Medeiros, a a, 1995. A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrob. Agents Chemother.* 39, 1211–1233. doi:10.1128/AAC.39.6.1211
- Callefi, L., Medeiros, E., Campos Furtado, G., 2012. Predictors of 14-day mortality in patients with bloodstream infections caused by *Enterobacteriaceae* strains: A mathematical PK/PD analysis. *Brazilian J. Infect. Dis.* 16, 211–213. doi:10.1016/S1413-8670(12)70310-0
- Cartelle, M., Del Mar Tomas, M., Pertega, S., Beceiro, A., Dominguez, M.A., Velasco, D., Molina, F., Villanueva, R., Bou, G., 2004. Risk factors for colonization and infection in a hospital outbreak caused by a strain of *Klebsiella pneumoniae* with reduced susceptibility to expanded-spectrum sefalosporins. *J. Clin. Microbiol.* 42, 4242–4249. doi:10.1128/JCM.42.9.4242-4249.2004
- Chang, Y.Y., Chuang, Y.C., Siu, L.K., Wu, T.L., Lin, J.C., Lu, P.L., Wang, J.T.,

- Wang, L.S., Lin, Y.T., Huang, L.J., Fung, C.P., 2014. Clinical features of patients with carbapenem nonsusceptible *Klebsiella pneumoniae* and *Escherichia coli* in intensive care units: A nationwide multicenter study in Taiwan. *J. Microbiol. Immunol. Infect.* 48, 219–225. doi:10.1016/j.jmii.2014.05.010
- Chen, C., Chen, Y., Wu, P., Chen, B., 2014. Update on new medicinal applications of gentamicin: Evidence-based review. *J. Formos. Med. Assoc.* 113, 72–82. doi:10.1016/j.jfma.2013.10.002
- Cheng, W.-L., Hsueh, P.-R., Lee, C.-C., Li, C.-W., Li, M.-J., Chang, C.-M., Lee, N.-Y., Ko, W.-C., 2014. Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*: Appropriateness of empirical treatment matters. *J. Microbiol. Immunol. Infect.* 1–8. doi:10.1016/j.jmii.2014.05.003
- Chetcuti Zammit, S., Azzopardi, N., Sant, J., 2014. Mortality risk score for *Klebsiella pneumoniae* bacteraemia. *Eur. J. Intern. Med.* 25, 1–6. doi:10.1016/j.ejim.2014.04.008
- Chiesa, C., Panero, A., Rossi, N., Stegagno, M., De Giusti, M., Osborn, J.F., Pacifico, L., 1998. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. *Clin. Infect. Dis.* 26, 664–72. doi:10.1086/514576
- Christ-Crain, M., Müller, B., 2005. Procalcitonin in bacterial infections--hype, hope, more or less? *Swiss Med. Wkly.* 135, 451–460. doi:2005/31/smw-11169
- Clermont, O., Bonacorsi, S., Bingen, E., 2000. Rapid and Simple Determination of the *E. coli* Phylogenetic group. *Appl. Environ. Microbiol.* 66, 4555–4558.
- Clermont, O., Lavollay, M., Vimont, S., Deschamps, C., Forestier, C., Branger, C., Denamur, E., Arlet, G., 2008. The CTX-M-15-producing *Escherichia coli* diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. *J. Antimicrob. Chemother.* 61, 1024–1028. doi:10.1093/jac/dkn084
- Cordery, R.J., Roberts, C.H., Cooper, S.J., Bellinghan, G., Shetty, N., 2008. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella* species in the intensive care unit; antibiotic management and clinical outcome. *J. Hosp. Infect.* 68, 108–115. doi:10.1016/j.jhin.2007.10.011
- de Kraker, M.E., Davey, P., Grundmann, H., 2011. Mortality and hospital stay associated with resistant *Staphylococcus aureus* and *Escherichia coli* bacteremia: Estimating the burden of antibiotic resistance in Europe. *PLoS Med.* 8. doi:10.1371/journal.pmed.1001104
- Durdu, B., Hakyemez, I.N., Bolukcu, S., Okay, G., Gultepe, B., Aslan, T., 2016. Mortality markers in nosocomial *Klebsiella pneumoniae* bloodstream infection.

Springerplus 5, 1892. doi:10.1186/s40064-016-3580-8

- Fair, R.J., Tor, Y., 2014. Antibiotics and Bacterial Resistance in the 21st Century. *Perspect. Medicin. Chem.* 25–64. doi:10.4137/PMC.S14459.Received
- Falagas, M.E., Karageorgopoulos, D.E., 2009. Extended-spectrum β -lactamase-producing organisms. *J. Hosp. Infect.* 73, 345–354. doi:10.1016/j.jhin.2009.02.021
- Fang, C.-T., Chuang, Y.-P., Shun, C.-T., Chang, S.-C., Wang, J.-T., 2004. A novel virulence gene in *Klebsiella pneumoniae* strains causing primary liver abscess and septic metastatic complications. *J. Exp. Med.* 199, 697–705. doi:10.1084/jem.20030857
- Fang, C.-T., Lai, S.-Y., Yi, W.-C., Hsueh, P.-R., Liu, K.-L., Chang, S.-C., 2007. *Klebsiella pneumoniae* Genotype K1: An Emerging Pathogen That Causes Septic Ocular or Central Nervous System Complications from Pyogenic Liver Abscess. *Clin. Infect. Dis.* 45, 284–293. doi:10.1086/519262
- Farooq, S., Hayakawa, K., Marchaim, D., Pogue, J.M., Kaye, K.S., 2014. Extended-spectrum β -lactamase-producing *Escherichia coli* isolation among older adults: Epidemiology and outcomes. *AJIC* 42, 565–568. doi:10.1016/j.ajic.2014.01.015
- Ferjani, S., Saidani, M., Amine, F.S., Boutiba Ben Boubaker, I., 2015. A comparative study of antimicrobial resistance rates and phylogenetic groups of community-acquired versus hospital-acquired invasive *Escherichia coli*. *Médecine Mal. Infect.* 45, 133–138. doi:10.1016/j.medmal.2015.01.012
- Flokas, M.E., Karanika, S., Alevizakos, M., Mylonakis, E., 2017. Prevalence of ESBL-producing *Enterobacteriaceae* in pediatric bloodstream infections: A systematic review and meta-analysis. *PLoS One* 12, 1–13. doi:10.1371/journal.pone.0171216
- Frazer, B.W., Hansen, S., Lambert, L., 2009. Invasive Infection With Hypermucoviscous *Klebsiella pneumoniae*: Multiple Cases Presenting to a Single Emergency Department in the United States. *Ann Emerg Med* 53, 639–642. doi:10.1016/j.annemergmed. 2008.11.007
- Freeman, J.T., McBride, S.J., Nisbet, M.S., Gamble, G.D., Williamson, D. a., Taylor, S.L., Holland, D.J., 2012. Bloodstream infection with extended-spectrum beta-lactamase-producing *Enterobacteriaceae* at a tertiary care hospital in New Zealand: Risk factors and outcomes. *Int. J. Infect. Dis.* 16, e371–e374. doi:10.1016/j.ijid.2012.01.008
- Garner, J., Jarvis, W., Emori, T., Horan, T., Hughes, J., Georgia, A., 1988. CDC definitions for nosocomial infections, 1998. *Am J Infect Control* 16, 128–40.
- Gupta, N., Limbago, B.M., Patel, J.B., Kallen, A.J., 2011. Carbapenem-resistant

- enterobacteriaceae: Epidemiology and prevention. Clin. Infect. Dis. 53, 60–67. doi:10.1093/cid/cir202
- Ha, Y., Kang, C., Cha, M., Park, S., Wi, Y., Chung, D., Peck, K., Lee, N., Song, J., 2013. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β -lactamase-producing *Escherichia coli* in patients with cancer. Int J Antimicrob Agents 42, 403–9. doi:10.1016/j.ijantimicag.2013.07.018
- Harris, P.N. a, Tambyah, P. a, Paterson, D.L., 2015. β -lactam and β -lactamase inhibitor combinations in the treatment of extended-spectrum β -lactamase producing *Enterobacteriaceae*: time for a reappraisal in the era of few antibiotic options? Lancet Infect. Dis. 15, 475–485. doi:10.1016/S1473-3099(14)70950-8
- Herwana, E., Pudjiadi, L., Surjawidjaja, J.E., 2008. Prevalence of extended spectrum beta-lactamase in *Klebsiella pneumoniae* 27.
- Hoeboer, S.H., van der Geest, P.J., Nieboer, D., Groeneveld, A.B.J., 2015. The diagnostic accuracy of procalcitonin for bacteraemia: A systematic review and meta-analysis. Clin. Microbiol. Infect. 21, 474–481. doi:10.1016/j.cmi.2014.12.026
- Ito, A., Ishida, T., Tokumasu, H., Washio, Y., Yamazaki, A., Ito, Y., Tachibana, H., 2017. Impact of procalcitonin-guided therapy for hospitalized community-acquired pneumonia on reducing antibiotic consumption and costs in Japan. J. Infect. Chemother. 23, 142–147. doi:10.1016/j.jiac.2016.11.006
- Kang, C., Kim, S., Park, W.B., Kim, H., Kim, E., Oh, M., Choe, K., Lee, K., 2004. Bloodstream Infections Due to Beta-Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae*: Risk Factors for Mortality and Treatment Outcome , with Special Emphasis on Antimicrobial Therapy Bloodstream Infections Due to Extended-Spectrum β - Lactam. Antimicrob Agents Chemother 48, 4574–4581. doi:10.1128/AAC.48.12.4574
- Kang, C.I., Cha, M.K., Kim, S.H., Wi, Y.M., Chung, D.R., Peck, K.R., Lee, N.Y., Song, J.H., 2014. Extended-spectrum sefalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β -lactamase-producing *Escherichia coli*: Potential clinical implications of the revised CLSI interpretive criteria. Int. J. Antimicrob. Agents 43, 456–459. doi:10.1016/j.ijantimicag.2014.01.030
- Kanoksil, M., Jatapai, A., Peacock, S.J., Limmathurotsakul, D., 2013. Epidemiology, Microbiology and Mortality Associated with Community-Acquired Bacteremia in Northeast Thailand: A Multicenter Surveillance Study. PLoS One 8, e54714. doi:10.1371/journal.pone.0054714
- Kawai, T., 2006. Hypermucoviscosity: an extremely sticky phenotype of *Klebsiella pneumoniae* associated with emerging destructive tissue abscess syndrome. CID 42, 1359–1361. doi:10.1086/503429

- Ku, N.S., Kim, Y., Kim, M., Song, J., Oh, D., Ahn, J., Kim, S., Kim, H., Jeong, S., Han, S., Kim, C., Song, Y., Kim, J., Choi, J., 2014. Risk factors for 28-day mortality in elderly patients with extended-spectrum β -lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella pneumoniae* bacteremia. Arch. Gerontol. Geriatr. 58, 105–109. doi:10.1016/j.archger.2013.07.002
- Ku, N.S., Kim, Y.C., Kim, M.H., Song, J.E., Oh, D.H., Ahn, J.Y., Kim, S.B., Kim, H.W., Jeong, S.J., Han, S.H., Kim, C.O., Song, Y.G., Kim, J.M., Choi, J.Y., 2014. Risk factors for 28-day mortality in elderly patients with extended-spectrum β -lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella pneumoniae* bacteremia. Arch Gerontol Geriatr 58, 105–109. doi:10.1016/j.archger.2013.07.002
- Lam, S.W., Bauer, S.R., Duggal, A., 2016. Procalcitonin-based algorithms to initiate or stop antibiotic therapy in critically ill patients: Is it time to rethink our strategy? Int. J. Antimicrob. Agents 47, 20–27. doi:10.1016/j.ijantimicag.2015.10.017
- Laupland, K.B., 2013. Incidence of bloodstream infection: a review of population-based studies. Clin. Microbiol. Infect. 19, 492–500. doi:10.1111/1469-0691.12144
- Lee, C., Cho, I., Jeong, B., Lee, S., 2013. Strategies to Minimize Antibiotic Resistance. Int. J. Environ. Res. Public Heal. 10, 4274–4305. doi:10.3390/ijerph10094274
- Lee, C.H., Liu, J.W., Su, L.H., Chien, C.C., Li, C.C., Yang, K.D., 2010. Hypermucoviscosity associated with *Klebsiella pneumoniae*-mediated invasive syndrome: A prospective cross-sectional study in Taiwan. Int J Infect Dis 14, e688–e692. doi:10.1016/j.ijid.2010.01.007
- Lee, N.Y., Huang, W.H., Tsui, K.C., Hsueh, P.R., Ko, W.C., 2011. Carbapenem therapy for bacteremia due to extended-spectrum β -lactamase-producing *Escherichia coli* or *Klebsiella pneumoniae*. Diagn Microbiol Infect Dis 70, 150–153. doi:10.1016/j.diagmicrobio.2010.12.008
- Leistner, R., Bloch, A., Gastmeier, P., Schwab, F., 2016. *E. coli* bacteremia in comparison to *K. pneumoniae* bacteremia: influence of pathogen species and ESBL production on 7-day mortality. Antimicrob. Resist. Infect. Control 5, 37. doi:10.1186/s13756-016-0138-z
- Lin, H.A., Huang, Y.L., Yeh, K.M., Siu, L.K., Lin, J.C., Chang, F.Y., 2016. Regulator of the mucoid phenotype A gene increases the virulent ability of extended-spectrum beta-lactamase-producing serotype non-K1/K2 *Klebsiella pneumoniae*. J. Microbiol. Immunol. Infect. 49, 494–501. doi:10.1016/j.jmii.2014.08.023
- Lin, J.C., Chang, F.Y., Fung, C.P., Xu, J.Z., Cheng, H.P., Wang, J.J., Huang, L.Y.,

- Siu, L.K., 2004. High prevalence of phagocytic-resistant capsular serotypes of *Klebsiella pneumoniae* in liver abscess. *Microbes Infect.* 6, 1191–1198. doi:10.1016/j.micinf.2004.06.003
- Livermore, D.M., 2008. Defining an extended-spectrum β -lactamase. *Clin. Microbiol. Infect.* 14, 3–10. doi:10.1111/j.1469-0691.2007.01857.x
- Livermore, D.M., 2003. Bacterial Resistance : Origins , Epidemiology , and Impact 36, 11–23.
- Lo, C.-L., Lee, C.-C., Li, C.-W., Li, M.-C., Hsueh, P.-R., Lee, N.-Y., Ko, W.-C., 2017. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*. *J. Microbiol. Immunol. Infect.* 50, 355–361. doi:10.1016/j.jmii.2015.08.012
- Lucasti, C., Popescu, I., Ramesh, M.K., Lipka, J., Sable, C., 2013. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: Results of a randomized, double-blind, phase II trial. *J. Antimicrob. Chemother.* 68, 1183–1192. doi:10.1093/jac/dks523
- Magret, M., Lisboa, T., Martin-Loeches, I., Máñez, R., Nauwynck, M., Wrigge, H., Cardellino, S., Díaz, E., Koulenti, D., Rello, J., 2011. Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. *Crit. Care* 15, R62. doi:10.1186/cc10036
- Marra, A.R., Wey, S.B., Castelo, A., Gales, A.C., Cal, R.G.R., Filho, J.R.D.C., Edmond, M.B., Pereira, C.A.P., 2006. Nosocomial bloodstream infections caused by *Klebsiella pneumoniae*: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. *BMC Infect. Dis.* 6, 24. doi:10.1186/1471-2334-6-24
- Mehl, A., Åsvold, B.O., Kümmel, A., Lydersen, S., Paulsen, J., Haugan, I., Solligård, E., Damås, J.K., Harthug, S., Edna, T.-H., 2017. Trends in antimicrobial resistance and empiric antibiotic therapy of bloodstream infections at a general hospital in Mid-Norway: a prospective observational study. *BMC Infect. Dis.* 17, 116. doi:10.1186/s12879-017-2210-6
- Melzer, M., Petersen, I., 2007. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing *E. coli* compared to non-ESBL producing *E. coli*. *J. Infect.* 55, 254–259. doi:10.1016/j.jinf.2007.04.007
- Metan, G., Zarakolu, P., Cakir, B., Hascelik, G., Uzun, O., 2005. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing *Escherichia coli*. *Int J Antimicrob Agents* 26, 254–257. doi:10.1016/j.ijantimicag.2005.06.012

- Mingeot-Leclercq, M.P., Glupczynski, Y., Tulkens, P.M., 1999. Aminoglycosides: Activity and resistance. *Antimicrob. Agents Chemother.* 43, 727–737.
- Mishra, S.K., Shrestha, R., Rijal, B.P., Pokhrel, B.M., 2015. The bad, the ugly and the demon: A tale of extensively drug-resistant, extended-spectrum-beta-lactamase- and metallo-beta-lactamase-producing superbugs associated with nosocomial pneumonia. *Asian Pacific J. Trop. Dis.* 5, 71–76. doi:10.1016/S2222-1808(14)60630-7
- Mosqueda-Gómez, J.L., Montaña-Loza, A., Rolón, A.L., Cervantes, C., Bobadilla-del-Valle, J.M., Silva-Sánchez, J., Garza-Ramos, U., Villasís-Keever, A., Galindo-Fraga, A., Palacios, G.M.R., Ponce-de-León, A., Sifuentes-Osornio, J., 2008. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum β -lactamase-producing *Klebsiella pneumoniae*. A case-control study. *Int. J. Infect. Dis.* 12, 653–659. doi:10.1016/j.ijid.2008.03.008
- Moyo, S.J., Aboud, S., Kasubi, M., Lyamuya, E.F., Maselle, S.Y., 2010. Antimicrobial resistance among producers and non-producers of extended spectrum beta-lactamases in urinary isolates at a tertiary Hospital in Tanzania. *BMC Res. Notes* 3, 348. doi:10.1186/1756-0500-3-348
- Murray, C.J.L., Lopez, A.D., 1999. On the Comparable Quantification of Health Risks : Lessons from the Global Burden of Disease Study. *Epidemiology* 10, 594–605.
- Nagano, R.I.E., Adachi, Y., Imamura, H., Yamada, K., Tsukuba, B., 2000. Carbapenem Derivatives as Potential Inhibitors of Various β -Lactamases , Including Class B Metallo- β -Lactamases 43, 2497–2503.
- Nasa, P., Juneja, D., Singh, O., Dang, R., Singh, A., 2012. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: Incidence, risk factors and its impact on outcome. *Eur. J. Intern. Med.* 23, 192–195. doi:10.1016/j.ejim.2011.06.016
- Neuner, E. a., Yeh, J.Y., Hall, G.S., Sekeres, J., Endimiani, A., Bonomo, R. a., Shrestha, N.K., Fraser, T.G., Van Duin, D., 2011. Treatment and outcomes in carbapenem-resistant *Klebsiella pneumoniae* bloodstream infections. *Diagn. Microbiol. Infect. Dis.* 69, 357–362. doi:10.1016/j.diagmicrobio.2010.10.013
- Nguyen, H.M., Shier, K.L., Graber, C.J., 2014. Determining a clinical framework for use of cefepime and β -lactam/ β -lactamase inhibitors in the treatment of infections caused by extended-spectrum- β -lactamase-producing Enterobacteriaceae. *J Antimicrob Chemother* 69, 871–880. doi:10.1093/jac/dkt450
- O'Neill, J., 2014. Antimicrobial Resistance : Tackling a crisis for the health and

wealth of nations.

- Oliphant, C.M., Green, G.M., 2002. Quinolones: A comprehensive review. *Am. Fam. Physician* 65, 455–464. doi:10.3109/13880209.2010.497815
- Özcengiz, G., 2017. Antibiotics : Pharmacokinetics , toxicity , resistance and multidrug efflux pumps 133, 43–62. doi:10.1016/j.bcp.2016.10.005
- Papp-wallace, K.M., Endimiani, A., Taracila, M.A., Bonomo, R.A., 2011. MINIREVIEW Carbapenems : Past , Present , and Future □ 55, 4943–4960. doi:10.1128/AAC.00296-11
- Park, B.S., Kim, S.E., Park, S.H., Kim, J., Shin, K.J., Ha, S.Y., Park, J., Kim, S.E., Lee, B.I., Park, K.M., 2017. Procalcitonin as a potential predicting factor for prognosis in bacterial meningitis. *J. Clin. Neurosci.* 36, 129–133. doi:10.1016/j.jocn.2016.10.005
- Paterson, D. L. Bonomo, R.A., 2005. Extended-Spectrum β -Lactamases : a Clinical Update. *Clin. Microbiol. Rev.* 18, 657–686. doi:10.1128/CMR.18.4.657
- Paterson, D.L., Ko, W.-C., Von Gottberg, A., Mohapatra, S., Casellas, J.M., Goossens, H., Mulazimoglu, L., Trenholme, G., Klugman, K.P., Bonomo, R. a, Rice, L.B., Wagener, M.M., McCormack, J.G., Yu, V.L., 2004a. Antibiotic therapy for *Klebsiella pneumoniae* bacteremia: implications of production of extended-spectrum beta-lactamases. *Clin Infect Dis* 39, 31–37. doi:10.1086/420816
- Paterson, D.L., Ko, W., Gottberg, A. Von, Mohapatra, S., Casellas, J.M., 2004b. International Prospective Study of *Klebsiella pneumoniae* Bacteremia : Implications of Extended-Spectrum β -Lactamase Production in. *Ann Intern Med.* 140, 26–32.
- Picard, B., Garcia, J., Gouriou, S., Duriez, P., Brahimi, N., Bingen, E., Elion, J., Denamur, E., 1999. The link between phylogeny and virulence in *Escherichia coli* extraintestinal infection? *Infect Immun.*, 67, 546–553.
- Plebani, M., Sciacovelli, L., Aita, a., Padoan, a., Chiozza, M.L., 2014. Quality indicators to detect pre-analytical errors in laboratory testing. *Clin. Chim. Acta* 432, 44–48. doi:10.1016/j.cca.2013.07.033
- Qureshi, Z., Paterson, D., Peleg, A., Adams-Haduch, J., Shutt, K., Pakstis, D., Sordillo, E., Polsky, B., Sandkovsky, G., Bhussar, M., Doi, Y., 2012. Clinical characteristics of bacteraemia caused by extended-spectrum beta-lactamase-producing *Enterobacteriaceae* in the era of CTX-M-type and KPC-type beta-lactamases. *Clin. Microbiol. Infect.* 18, 887–893. doi:10.1111/j.1469-0691.2011.03658.x
- Rath, S., Dubey, D., Sahu, M.C., Debata, N.K., Padhy, R.N., 2014. Surveillance of ESBL producing multidrug resistant *Escherichia coli* in a teaching hospital in

- India. *Asian Pacific J. Trop. Dis.* 4, 140–149. doi:10.1016/S2222-1808(14)60331-5
- Rodríguez-Baño, J., Mingorance, J., Fernández-Romero, N., Serrano, L., López-Cerero, L., Pascual, A., 2013. Outcome of bacteraemia due to extended-spectrum β -lactamase-producing *Escherichia coli*: Impact of microbiological determinants. *J. Infect.* 67, 27–34. doi:10.1016/j.jinf.2013.04.006
- Rodríguez-Baño, J., Picón, E., Gijón, P., Hernández, J.R., Ruíz, M., Peña, C., Almela, M., Almirante, B., Grill, F., Colomina, J., Giménez, M., Oliver, A., Horcajada, J.P., Navarro, G., Coloma, A., Pascual, A., 2010. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing *Escherichia coli*: risk factors and prognosis. *Clin. Infect. Dis.* 50, 40–48. doi:10.1086/649537
- Rothman, K.J., Greenland, S., 2005. Causation and Causal Inference in Epidemiology. *Am J Public Heal.* 95, 144–150. doi:10.2105/AJPH.2004.059204
- Rottier, W.C., Ammerlaan, H.S.M., Bonten, M.J.M., 2012. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β -lactamase-producing enterobacteriaceae and patient outcome: A meta-analysis. *J. Antimicrob. Chemother.* 67, 1311–1320. doi:10.1093/jac/dks065
- Schwaber, M.J., Carmeli, Y., 2007. Mortality and delay in effective therapy associated with extended-spectrum β -lactamase production in *Enterobacteriaceae* bacteraemia: a systematic review and meta-analysis 913–920. doi:10.1093/jac/dkm318
- Shiber, S., Yahav, D., Avni, T., Leibovici, L., Paul, M., 2014. β Lactam/ β -lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother* 70, 41–47. doi:10.1093/jac/dku351
- Shon, A.S., Bajwa, R.P.S., Russo, T.A., 2013. Hypervirulent (hypermucoviscous) *Klebsiella pneumoniae*: a new and dangerous breed. *Virulence* 4, 107–18. doi:10.4161/viru.22718
- Skippen, I., Shemko, M., Turton, J., Kaufmann, M.E., Palmer, C., Shetty, N., 2006. Epidemiology of infections caused by extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella spp.*: a nested case-control study from a tertiary hospital in London. *J. Hosp. Infect.* 64, 115–123. doi:10.1016/j.jhin.2006.05.010
- Son, J., Song, J., Ko, K., Yeom, J., Ki, H., Kim, S., Chang, H., Ryu, S., Kim, Y., Jung, S., Shin, S., Oh, H., Lee, Y., Chung, D., Lee, N., Peck, K., 2010. Bloodstream infections and clinical significance of health care associated bacteremia: A multicenter surveillance study in Korean hospitals. *JKMS* 25,

992–998. doi:10.3346/jkms.2010.25.7.992

- Tang, B.M.P., Eslick, G.D., Craig, J.C., McLean, A.S., 2007. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. *Lancet Infect. Dis.* 7, 210–7. doi:10.1016/S1473-3099(07)70052-X
- Tian, L., Tan, R., Chen, Y., Sun, J., Liu, J., Qu, H., Wang, X., 2016. Epidemiology of *Klebsiella pneumoniae* bloodstream infections in a teaching hospital: factors related to the carbapenem resistance and patient mortality. *Antimicrob. Resist. Infect. Control* 5, 48. doi:10.1186/s13756-016-0145-0
- To, K.K., Lo, W., Chan, J.F., Tse, H., Cheng, V.C., Ho, P.L., 2013. Clinical outcome of extended-spectrum beta-lactamase-producing *Escherichia coli* bacteremia in an area with high endemicity. *Int J Infect Dis* 17, e120–e124. doi:10.1016/j.ijid.2012.09.008
- Trecarichi, E.M., Tumbarello, M., Spanu, T., Caira, M., Fianchi, L., Chiusolo, P., Fadda, G., Leone, G., Cauda, R., Pagano, L., 2009. Incidence and clinical impact of extended-spectrum- β -lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by *Escherichia coli* in patients with hematological malignancies. *J. Infect.* 58, 299–307. doi:10.1016/j.jinf.2009.02.002
- Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E.M., Tumietto, F., Marchese, A., Spanu, T., Ambretti, S., Ginocchio, F., Cristini, F., Losito, A.R., Tedeschi, S., Cauda, R., Bassetti, M., 2012. Predictors of mortality in bloodstream infections caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: Importance of combination therapy. *Clin. Infect. Dis.* 55, 943–950. doi:10.1093/cid/cis588
- Tuon, F., Kruger, M., Terreri, M., Pentead-Filho, S., Gortz, L., 2011. *Klebsiella* ESBL bacteremia-mortality and risk factors. *Braz. j. infect. dis.*, 15, 594–598. doi:10.1016/S1413-8670(11)70257-4
- Tzouveleki, L.S., Markogiannakis, a., Psychogiou, M., Tassios, P.T., Daikos, G.L., 2012. Carbapenemases in *Klebsiella pneumoniae* and other *Enterobacteriaceae*: An evolving crisis of global dimensions. *Clin. Microbiol. Rev.* 25, 682–707. doi:10.1128/CMR.05035-11
- Vardakas, K.Z., Rafailidis, P.I., Konstantelias, A. a., Falagas, M.E., 2013. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: The study, the patient, the bug or the drug? *J. Infect.* 66, 401–414. doi:10.1016/j.jinf.2012.10.028
- Vardakas, K.Z., Tansarli, G.S., Rafailidis, P.I., Falagas, M.E., 2012. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to enterobacteriaceae producing extended-spectrum β -lactamases: A systematic

- review and meta-analysis. *J Antimicrob Chemother* 67, 2793–2803.
doi:10.1093/jac/dks301
- Wang, S.-S., Lee, N.-Y., Hsueh, P.-R., Huang, W.-H., Tsui, K.-C., Lee, H.-C., Wu, C.-J., Chang, C.-M., Huang, C.-C., Huang, C.-F., Ko, W.-C., 2011. Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β -lactamase-producing *Escherichia coli* or *Klebsiella pneumoniae*. *J. Microbiol. Immunol. Infect.* 44, 282–288.
doi:10.1016/j.jmii.2010.08.004
- Weinstein, R. a., Logan, L.K., 2012. Carbapenem-resistant enterobacteriaceae: An emerging problem in children. *Clin. Infect. Dis.* 55, 852–859.
doi:10.1093/cid/cis543
- WHO, 2014. ANTIMICROBIAL RESISTANCE Global Report on Surveillance 2014. World Heal. Organ.
- Wiskur, B.J., Hunt, J.J., Callegan, M.C., 2008. Hypermucoviscosity as a virulence factor in experimental *Klebsiella pneumoniae* endophthalmitis. *Invest Ophthalmol Vis Sci* 49, 4931–4938. doi:10.1167/iovs.08-2276
- Wu, U.-I., Yang, C.-S., Chen, W.-C., Chen, Y.-C., Chang, S.-C., 2010. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing *Escherichia coli*. *J. Microbiol. Immunol. Infect.* 43, 310–316.
doi:10.1016/S1684-1182(10)60048-5
- Yan, S.T., Sun, L.C., Jia, H.B., Gao, W., Yang, J.P., Zhang, G.Q., 2017. Procalcitonin levels in bloodstream infections caused by different sources and species of bacteria. *Am. J. Emerg. Med.* 35, 579–583.
doi:10.1016/j.ajem.2016.12.017
- Yang, C.-C., Wu, C.-H., Lee, C.-T., Liu, H.-T., Chen, J.-B., Chiu, C.-H., Chen, C.-H., Chuang, F.-R., 2014. Nosocomial extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* bacteremia in hemodialysis patients and the implications for antibiotic therapy. *Int. J. Infect. Dis.* 28, 3–7.
doi:10.1016/j.ijid.2014.07.012
- Yu, W.-L., Ko, W.-C., Cheng, K.-C., Lee, H.-C., Ke, D.-S., Lee, C.-C., Fung, C.-P., Chuang, Y.-C., 2006. Association between *rmpA* and *magA* genes and clinical syndromes caused by *Klebsiella pneumoniae* in Taiwan. *CID* 42, 1351–1358.
doi:10.1086/503420
- Zhanel, G.G., Walkty, A., Vercaigne, L., Karlowsky, J.A., Embil, J., Gin, A.S., Hoban, D.J., 1999. The new fluoroquinolones: A critical review. *Can J Infect Dis* 10, 207–38.